ILUSTRASI. Pfizer Inc looks to boost its pipeline to combat a potential slowdown in Covid product demand that analysts anticipate from falling cases. REUTERS/Dado Ruvic
Sumber: Reuters | Editor: Anastasia Lilin Yuliantina
KONTAN.CO.ID - Pfizer Inc will buy blood disorder drugmaker Global Blood Therapeutics in a US$ 5,4 billion deal, as it looks to boost its pipeline to combat a potential slowdown in Covid product demand that analysts anticipate from falling cases.
New York-based Pfizer, flush with cash from sales of its Covid-19 vaccine last year, has been on the lookout for acquisitions that could bring in billions in annual sales by the end of the decade.
Agar bisa lanjut membaca sampai tuntas artikel ini, pastikan Anda sudah berlangganan atau membeli artikel ini.
Sudah berlangganan? Masuk
Berlangganan Hanya dengan 20rb/bulan Anda bisa mendapatkan berita serta analisis ekonomi, bisnis, dan investasi pilihan
Hanya Rp 5.000 untuk membaca artikel ini
Anda dapat menggunakan akun Google sebagai metode pembayaran karena Google akan mengingat metode yang sudah pernah digunakan.
